| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Review
- Language: English
- [Top Magn Reson Imaging] 2020 Apr; Vol. 29 (2), pp. 71-82.
- MeSH Terms: Brain Neoplasms / *classification ; Brain Neoplasms / *genetics ; Glioma / *classification ; Glioma / *genetics ; Magnetic Resonance Imaging / *methods ; Adult ; Biomarkers, Tumor ; Brain / diagnostic imaging ; Brain Neoplasms / diagnostic imaging ; Genomics ; Glioma / diagnostic imaging ; Humans ; Prognosis ; Radiologists ; World Health Organization
- References: DeWeerdt S. The genomics of brain cancer. Nature 2018; 561:S54–S55. ; Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97–109. ; Coons SW, Johnson PC, Scheithauer BW, et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997; 79:1381–1393. ; van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 2010; 120:297–304. ; Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807–1812. ; Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765–773. ; Ransom DT, Ritland SR, Kimmel DW, et al. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes Cancer 1992; 5:348–356. ; Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66:9852–9861. ; Riemenschneider MJ, Jeuken JW, Wesseling P, et al. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 2010; 120:567–584. ; Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26:2192–2197. ; Raabe EH, Lim KS, Kim JM, et al. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res 2011; 17:3590–3599. ; Johnson A, Severson E, Gay L, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist 2017; 22:1478–1490. ; Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131:803–820. ; Karremann M, Gielen GH, Hoffmann M, et al. Diffuse high-grade gliomas with H3 K27 M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol 2018; 20:123–131. ; Haase S, Garcia-Fabiani MB, Carney S, et al. Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin Ther Targets 2018; 22:599–613. ; Leeper HE, Caron AA, Decker PA, et al. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget 2015; 6:30295–30305. ; Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013; 126:443–451. ; Yousem DM, Gad K, Tufano RP. Resectability issues with head and neck cancer. AJNR Am J Neuroradiol 2006; 27:2024–2036. ; Wang X, Chen JX, Liu JP, et al. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. Ann Surg Oncol 2014; 21:1337–1344. ; Gillet E, Alentorn A, Doukoure B, et al. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. J Neurooncol 2014; 118:131–139. ; Liu J, Zhang X, Yan X, et al. Significance of TERT and ATRX mutations in glioma. Oncol Lett 2019; 17:95–102. ; Lee Y, Koh J, Kim SI, et al. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Acta Neuropathol Commun 2017; 5:62. ; Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014; 24:429–435. ; Brat DJ, Verhaak RG, Aldape KD, et al. Cancer Genome Atlas Research NetworkComprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372:2481–2498. ; Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014; 32:783–790. ; Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 2016; 374:1344–1355. ; van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31:344–350. ; van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 2017; 390:1645–1653. ; Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 2018; 136:805–810. ; Smits M, van den Bent MJ. Imaging correlates of adult glioma genotypes. Radiology 2017; 284:316–331. ; Wang Y, Zhang T, Li S, et al. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas. Eur J Neurol 2015; 22:348–354. ; Qi S, Yu L, Li H, et al. Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 2014; 7:1895–1902. ; Carrillo JA, Lai A, Nghiemphu PL, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 2012; 33:1349–1355. ; Sherman JH, Prevedello DM, Shah L, et al. MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status. Acta Neurochir (Wien) 2010; 152:1827–1834. ; Kim JW, Park CK, Park SH, et al. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 2011; 82:224–227. ; Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004; 10:4303–4306. ; Jenkinson MD, du Plessis DG, Smith TS, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006; 129:1884–1891. ; Patel SH, Poisson LM, Brat DJ, et al. T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017; 23:6078–6085. ; Broen MPG, Smits M, Wijnenga MMJ, et al. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 2018; 20:1393–1399. ; Juratli TA, Tummala SS, Riedl A, et al. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol 2019; 141:327–335. ; Lasocki A, Gaillard F, Gorelik A, et al. MRI features can predict 1p/19q status in intracranial gliomas. AJNR Am J Neuroradiol 2018; 39:687–692. ; Johnson DR, Kaufmann TJ, Patel SH, et al. There is an exception to every rule-T2-FLAIR mismatch sign in gliomas. Neuroradiology 2019; 61:225–227. ; Drabycz S, Roldan G, de Robles P, et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 2010; 49:1398–1405. ; Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012; 4:116ra4. ; Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012; 18:624–629. ; Leather T, Jenkinson MD, Das K, et al. Magnetic resonance spectroscopy for detection of 2-hydroxyglutarate as a biomarker for IDH mutation in gliomas. Metabolites 2017; 7:pii: E29. ; Kickingereder P, Sahm F, Radbruch A, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 2015; 5:16238. ; Tan W, Xiong J, Huang W, et al. Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI. J Magn Reson Imaging 2017; 45:492–499. ; Yamashita K, Hiwatashi A, Togao O, et al. MR imaging-based analysis of glioblastoma multiforme: estimation of IDH1 mutation status. AJNR Am J Neuroradiol 2016; 37:58–65. ; Wu CC, Jain R, Radmanesh A, et al. Predicting genotype and survival in glioma using standard clinical mr imaging apparent diffusion coefficient images: a pilot study from the Cancer Genome Atlas. AJNR Am J Neuroradiol 2018; 39:1814–1820. ; Villanueva-Meyer JE, Wood MD, Choi BS, et al. MRI features and IDH mutational status of grade II diffuse gliomas: impact on diagnosis and prognosis. AJR Am J Roentgenol 2018; 210:621–628. ; Eichinger P, Alberts E, Delbridge C, et al. Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas. Sci Rep 2017; 7:13396. ; Van Cauter S, Veraart J, Sijbers J, et al. Gliomas: diffusion kurtosis MR imaging in grading. Radiology 2012; 263:492–501. ; Tietze A, Hansen MB, Ostergaard L, et al. Mean diffusional kurtosis in patients with glioma: initial results with a fast imaging method in a clinical setting. AJNR Am J Neuroradiol 2015; 36:1472–1478. ; Delgado AF, Fahlstrom M, Nilsson M, et al. Diffusion kurtosis imaging of gliomas grades II and III: a study of perilesional tumor infiltration, tumor grades and subtypes at clinical presentation. Radiol Oncol 2017; 51:121–129. ; Falk Delgado A, Nilsson M, van Westen D, et al. Glioma grade discrimination with MR diffusion kurtosis imaging: a meta-analysis of diagnostic accuracy. Radiology 2018; 287:119–127. ; Saadeh FS, Mahfouz R, Assi HI. EGFR as a clinical marker in glioblastomas and other gliomas. Int J Biol Markers 2018; 33:22–32.
- Substance Nomenclature: 0 (Biomarkers, Tumor)
- Entry Date(s): Date Created: 20200410 Date Completed: 20200924 Latest Revision: 20210213
- Update Code: 20231215
|
